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Abstract: Supplementation with inulin-propionate ester (IPE), which delivers propionate to the
colon, suppresses ad libitum energy intake and stimulates the release of satiety hormones acutely
in humans, and prevents weight gain. In order to determine whether IPE remains effective when
incorporated into food products (FP), IPE needs to be added to a widely accepted food system. A
bread roll and fruit smoothie were produced. Twenty-one healthy overweight and obese humans
participated. Participants attended an acclimatisation visit and a control visit where they consumed
un-supplemented food products (FP). Participants then consumed supplemented-FP, containing
10 g/d inulin or IPE for six days followed by a post-supplementation visit in a randomised crossover
design. On study visits, supplemented-FP were consumed for the seventh time and ad libitum
energy intake was assessed 420 min later. Blood samples were collected to assess hormones and
metabolites. Resting energy expenditure (REE) was measured using indirect calorimetry. Taste and
appearance ratings were similar between FP. Ad libitum energy intake was significantly different
between treatments, due to a decreased intake following IPE-FP. These observations were not related
to changes in blood hormones and metabolites. There was an increase in REE following IPE-FP.
However, this effect was lost after correcting for changes in fat free mass. Our results suggest that IPE
suppresses appetite and may alter REE following its incorporation into palatable food products.
Keywords: SCFA; propionate; appetite; energy intake; energy expenditure
1. Introduction
A number of epidemiological studies have shown that increased dietary fibre intake protects
against weight gain [1–3]. Intervention studies in animals also support this observation [4,5]. It has
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been suggested that the positive effects associated with fibre are partly attributable to short-chain fatty
acids (SCFA), products of fibre fermentation. The SCFA propionate has been shown to stimulate the
release of the anorexigenic hormones peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) from
intestinal L-cells [6].
However, the degree of fermentation of dietary fibre and rate, site and extent of SCFA produced
varies across individuals [7]. Moreover, the levels of dietary fibre intake needed to stimulate the release
of gut hormones are not achievable in most Western societies [8]. Oral SCFA supplementation is not
a feasible dietary intervention strategy in humans because the very poor organoleptic properties of
SCFA prohibit consumption of the requisite doses for any significant duration. As a result, the majority
of current available evidence demonstrating positive metabolic effects of raising gut-derived SCFAs
has been obtained from animal models with few human studies. To overcome this problem we have
developed a method of delivering SCFA to the colon, the site of maximal production in the GI tract [9],
using inulin-SCFA esters. We have previously shown that selectively increasing propionate delivery to
the colon using inulin-propionate ester (IPE) reduces energy intake and increases circulating PYY and
GLP-1 concentrations acutely in humans, and prevents weight gain [10].
There is also evidence to suggest that propionate supplementation can prevent weight gain
independently of altered energy intake [10–12]. Oral propionate supplementation has been reported to
protect against diet-induced obesity by enhancing energy expenditure (EE) via an increase in lipid
oxidation in mice [11]. We have recently shown that acute oral sodium propionate supplementation
also increases resting EE (REE) and lipid oxidation in humans [13]. However, the potential effect of IPE
supplementation on energy expenditure and substrate oxidation has not previously been investigated.
In our previous studies, IPE was provided as a powder supplement which volunteers were asked
to mix with their habitual diet. The incorporation of IPE into food products (FP) would not only
standardise the way participants consume IPE for long-term studies but would also be an attractive
way to deliver IPE on a population scale. An additional important question is whether IPE changes the
palatability of common FP, since release of propionate in product preparation may “spoil” the product
because of the poor organoleptic properties of propionate. Here, a bread roll and fruit smoothie were
the FP used for supplementation of IPE. The aim of the present study was two-fold: (1) to confirm the
appetite-suppressing effects of IPE in healthy overweight and obese humans when incorporated into
palatable FP and; (2) to explore the effect of elevated colonic propionate on REE and substrate oxidation.
We hypothesised that an increase in colonic propionate delivery following a seven-day supplementation
period with IPE-FP would reduce ad libitum energy intake and this would be mediated by an increase
in PYY and GLP-1.
2. Materials and Methods
This was a randomised, double-blind, crossover feeding study, which was approved by the
London-Brent Research Ethics Committee (REC reference number 14/LO/0645) and registered on the
ISRCTN registry (ISRCTN71814178). This study was conducted in accordance with the Declaration of
Helsinki of 1975 and later revisions.
2.1. Participant Recruitment
Participants were recruited via existing volunteer databases and poster advertisements. Men
and women aged between 18–65 years with body mass index (BMI; kg/m2) 25–40 were eligible for
inclusion. Exclusion criteria included weight change of ≥3 kg in the preceding two months, current
smokers, excess alcohol intake, substance abuse, any chronic illness or GI disorder, pregnancy and
use of medications likely to interfere with energy metabolism, appetite regulation and hormonal
balance, including: anti-inflammatory drugs or steroids, antibiotics, androgens, phenytoin, or thyroid
hormones. Eligible participants were randomised into the study by the sealed envelope randomisation
service (www.sealedenvelope.com).
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2.2. Dietary Intervention
IPE, designed for targeted delivery of propionate to the colon, was the interventional supplement
used in this study and was produced in-house as previously described [10,14]. Inulin (Beneo HP, DKSH,
London, UK) was used as a positive control (10 g/d). Dietary supplements were incorporated into FP by
Leatherhead Food Research (Epsom, Surrey, UK) in order to standardise how participants consumed
them. A bread roll and fruit smoothie were the two FP chosen as the ‘vehicle’ for supplementation.
Supplemented-FP each contained either 5 g of IPE or 5 g of inulin, thus providing a total dose of 10 g/d
when consumed together. Unsupplemented FP (containing neither IPE nor inulin) were also produced
for Control visits. Apart for the addition of dietary supplements to the FP, all FP were identical and
were made in the same batch. The nutritional composition of food products, as assessed using DietPlan
6 (Forestfield Software Ltd., Horsham, West Sussex, UK), is shown in Table S1. The FP were frozen
post-production and were defrosted on the morning of consumption.
2.3. Study Design
An overview of the study design is outlined in Figure S1. This study involved 4 separate study
visits: (1) an “acclimatization” study visit, (2) a “control” study visit, (3) a “post-supplementation study
visit 1” following the first six-day feeding period, and (4) a final “post-supplementation study visit 2”
following the second six-day feeding period. Participants received un-supplemented FP (control-FP)
on the acclimatisation and control study visits with a seven-day washout period after both study visits.
In a randomised order, participants then consumed FP supplemented with either IPE (IPE-FP) or inulin
(inulin-FP) for 6 days followed by post-supplementation study visit 1, during which they received the
supplemented-FP for the seventh and final time. Following a 14-day washout period, participants
entered into the final six-day feeding period followed by post-supplementation study visit 2 where
they consumed the FP that they had not yet received.
2.4. Supplementation Period
Per supplementation period, participants were provided with six bread rolls and six smoothies and
asked to consume one of each product per day for the six days leading up to the post-supplementation
study visit. Participants were provided with a supplementation diary in order track the time and date
of product consumption and to monitor compliance.
2.5. Study Visit Preparation
Participants were asked to avoid caffeine, alcohol and strenuous exercise, and to record their food
intake for the 24 h before each study visit. A standard meal of the participant’s choice was consumed
the evening before each visit in order to promote consistency between visits. Participants were asked
to arrive having fasted for 12 h prior to each study visit. Participants were also asked not to start any
new diet or intensive exercise regimes during the study period in order to prevent conflicting results.
2.6. Study Visit Protocol
The study visit protocol is outlined in Figure S1. Study visits were conducted between October
2014 – February 2016 at the National Institute for Health Research (NIHR) Imperial Clinical Research
Facility (CRF), Hammersmith Hospital, London, United Kingdom.
Prior to the consumption of the test meal (0 min), body composition measurements were assessed
by bioelectrical impedance analysis (Tanita BC-418 analyser; Tanita Corporation, Tokyo, Japan).
Participants were asked to empty their bladders and change into a set of hospital scrubs prior to the
collection of body composition data, in order to promote consistency between visits. Participants
completed an international physical activity questionnaire (IPAQ), which captured data related to
physical activity levels during the previous seven days. Side effects experienced during the previous
seven days were also assessed using a series of 100 mm visual analogue scales (VAS). The left
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extremity of the VAS was labelled with ‘not at all’ and the right-hand extremity was labelled with
“severe problem”. In addition, a number of baseline samples were collected in duplicate (>5 min
apart). Baseline blood samples were collected via a peripheral cannula in order to assess metabolite
and hormone concentrations. Baseline breath H2 measurements were collected in real-time using a
handheld breath H2 m (Gastro+ Gastrolyser Breath Hydrogen Monitor; Bedfont Scientific, Maidstone,
Kent, UK). Baseline subjective feelings of appetite (“how hungry/full do you feel?”) and mood (“how
nauseous do you feel?”) were also collected using a series of 100 mm VAS. The left extremity of the VAS
was labelled with ‘not at all’ and the right-hand extremity was labelled with “extremely”. Participants
were asked to draw a vertical line on the VAS depending on how intensely they were experiencing
each feeling.
Overnight fasted REE and substrate oxidation was measured using open-circuit indirect calorimetry
(Gas Exchange Monitor, GEM Nutrition, Daresbury, Cheshire, UK). During the collection of REE data,
participants were asked to lie semi-supine and a transparent canopy was placed over their head and
thorax. Participants were permitted to watch television, read or listen to music while under the canopy
but were instructed to stay as still as possible. For the measurement of urinary nitrogen excretion,
participants were asked to collect all urine in a collection container for 420 min after consuming the
test meal.
Participants received a standardised breakfast (600 kcal; 114.6 g carbohydrate, 13.8 g fat, 15.6 g
protein, 7.1 g fibre) at 0 min, which consisted of the appropriate bread roll and smoothie according to
the participant’s randomisation along with breakfast cereal, milk and margarine. Following breakfast,
participants completed a product satisfaction questionnaire where they rated the product overall as
well as based on its appearance, aroma, flavour and texture. Participants ticked a box between 1 and 9,
where 1 was labelled with “dislike extremely”, 5 was labelled with “neither like nor dislike” and 9 was
labelled with “like extremely”. REE was measured before (~160–175 min) and after (~210–240 min) a
standardised snack (508 kcal, 57.1 g carbohydrate, 21.3 g fat, 20.7 g protein, 2.0 g fibre), which was
served at 180 min.
Further venous blood samples (15, 30, 60, 90, 120, 180, 195, 210, 240, 270, 300, 360, 420 min), VAS
(15, 30, 60, 90, 120, 180, 195, 240, 270, 300, 360, 420 min) and breath H2 concentration (60, 120, 180, 240,
300, 360 min) measurements were collected throughout the study visit.
After 420 min, the cannula was removed and participants were provided with an ad libitum meal.
This time point was chosen based on previous data suggesting successful delivery of IPE to the colon
at this time [10]. This was a savoury meal and participants were offered the choice of tomato and herb
pasta (per 100 g: 129 kcal; 21.0 g carbohydrate, 3.2 g fat, 3.3 g protein, 1.8 g fibre) or four cheese pasta
(per 100 g: 165 kcal; 21.5 g carbohydrate, 6.6 g fat, 4.3 g protein, 1.1 g fibre). Participants consumed
the same choice of buffet meal on the control and post-supplementation study visits. Participants
were instructed to eat until they felt comfortably full and the amount of food consumed was weighed.
Following the ad libitum meal, participants were discharged from the CRF.
An acclimatisation study visit was added to the protocol in order to introduce, or acclimatise,
participants to the study protocol [15]. The only difference between the acclimatisation study visit and
the other study visits was that a small amount of blood (1 mL) was taken at each time point and was
immediately discarded.
2.7. Blood Sample Preparation
Ten millilitres of blood was collected at each time point for assay of plasma glucose (BD Fluoride
EDTA Vacutainer; BD, New Jersey, USA), serum insulin and NEFA (BD Serum SST Vacutainer; BD,
New Jersey, USA) and plasma gut hormones (BD Lithium Heparin Vacutainer; BD, New Jersey, USA)
containing 20 µL/mL whole blood Aprotinin pancreatic protease inhibitor, Nordic Pharma UK Ltd.,
Reading, UK) measurements. Plasma tubes were centrifuged immediately at 2500 RCF for 10 min at
4 ◦C. Serum tubes were allowed to clot before centrifugation. Resulting plasma/serum was aliquoted
into Eppendorfs and frozen at −20 ◦C until analysis.
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2.8. Ad Libitum Energy Intake
Food intake data were collected for 19 participants. One participant’s food was disposed of before
obtaining data on food intake and one participant refused to consume any food at the buffet meals.
Food intake (g) was multiplied by the energy density of the meal in order to calculate the mean energy
intake at the ad libitum meal.
2.9. Visual Analogue Scales
A composite appetite score (CAS) was calculated using the following formula [16]: [Hunger +
(100 − Fullness) + Desire to Eat + Appetite for Meal]/4.
2.10. Energy Expenditure and Substrate Oxidation Measurement
REE, RER, and substrate oxidation were estimated from oxygen consumption and carbon dioxide
production using the following equations [17]:
RER = V·CO2/V·O2
REE = [(3.91 ∗ V·O2) + (1.1 ∗ V·CO2) − (1.93 ∗ N)]
Carbohydrate oxidation = [(4.57 ∗ V·CO2) − (3.23 ∗ V·O2) − (2.6 ∗ N)
Fat oxidation = [(1.69 ∗ V·O2) − (1.69 ∗ V·CO2) − (2.03 ∗ N)]
N = [((((CH4N2O/16.6) ∗ 0.466) ∗ vol)/time) ∗ 1.2]
Protein oxidation = [N ∗ 6.25]
where RER is the respiratory exchange ratio, REE is in kcal/min, V·O2 is the rate of oxygen consumed
in L/min, V·CO2 is the rate of carbon dioxide in L/min, N is urinary nitrogen in g/min, carbohydrate,
fat and protein oxidation are in g/min, CH4N2O is urinary urea in mmol/L, vol is the urine volume in L
and time is in min.
2.11. Metabolic and Hormone Analysis
A fasting blood sample was sent to the Dept. of Biochemistry, Hammersmith Hospital on each
study visit for cholesterol (total, HDL, LDL) and triglyceride measurement. An aliquot of urine
was also sent to the Dept. of Biochemistry for urinary urea quantification. Glucose analysis was
performed in the Dept. of Biochemistry, Hammersmith Hospital using a ci8200 analyser enzymatic
method (Abbott, Abbott Park, IL, USA). Insulin analysis was performed in-house using a human
insulin RIA kit (Millipore Corporation, Billerica, MA, USA) according to manufacturer’s guidelines
with 50 µL serum. PYY and GLP-1 were measured using previously established in-house specific
and sensitive RIA [18,19]. Acetate, propionate and butyrate were measured at Dept. of Cancer and
Surgery using an Agilent 7000C Triple Quadrupole GC/MS System (Agilent, Santa Clara, CA, USA)
according to a previously published method [20]. NEFA were measured using a commercial kit (FA115
NEFA kit; Randox, London, UK) and were measured using an ILAB 650 Clinical Chemistry Analyser
(Instrumentation Laboratory, Birchwood, Warrington, UK).
2.12. Statistics
It was estimated, using the G*Power power calculator, that 19 volunteers would be needed, based
on a power of 80%, α = 0.05, to detect a difference in mean plasma PYY concentration (primary outcome
measure) of 16 pmol/L with a standard deviation of 23 between treatments [10].
Data are presented as median [IQR]. The average of two separate measurements for breath H2,
CAS, blood hormone and metabolite data, which were collected before the test meal, were used for the
Nutrients 2019, 11, 861 6 of 18
0 min measurement, which is referred to as a baseline or fasting measurement. AUC were calculated
using the trapezoidal rule and divided by the relevant time period (180 or 240 min).
Owing to the non-parametric nature of the majority of outcome measures and in order to determine
the simple rank order of the three treatments (Control, Inulin and IPE), data were compared using
a Friedman test with post-hoc Wilcoxon signed-rank tests. Significance was considered p < 0.05.
Statistical analyses were performed using IBM SPSS Statistics v23-24 (Armonk, New York, USA).
Graphs were prepared using GraphPad Prism v5.0-7.0 (San Diego, CA, USA).
3. Results
Twenty-three participants were randomised into this study with 21 participants completing all
four study visits. Two participants withdrew from the study before attending their first study visit.
Twelve participants were randomly assigned to receive IPE-FP during the first supplementation period
and nine participants received inulin-FP first.
3.1. Participant Characteristics
An overview of participant characteristics on each study visit is given in Table 1. There were
no differences in fasting blood lipid profiles, power of food scale, IPAQ values or in food intake in
the 24 h prior to study visits. There were significant differences in body weight (p = 0.023) and FFM
(p = 0.024) among treatments (Table 1). Post hoc tests revealed that body weight was significantly
higher following IPE supplementation versus both inulin supplementation (p = 0.017) and control
(p = 0.04). There was no significant difference in body weight (p = 1.0) between inulin supplementation
and control. FFM was significantly higher following IPE supplementation (p = 0.001), when compared
to control. Compared to inulin supplementation, there was a trend for FFM to be higher on the control
visit (p = 0.073) and following IPE supplementation (p = 0.063). There was a significant difference in
total body water (TBW; p = 0.026) between the three treatments (Table 1). Post hoc tests revealed that
TBW was significantly higher following IPE supplementation versus both inulin supplementation
(p = 0.045) and control (p = 0.003). There was no significant difference in body weight between inulin
supplementation and control (p = 0.21) .
3.2. Ad Libitum Energy Intake, Gut Hormone Concentrations and Composite Appetite Score
There was a significant difference in ad libitum energy intake between treatments (p = 0.012;
Table 2). Post-hoc tests revealed that there was a trend for IPE to reduce food intake compared to control
(p = 0.056) and inulin supplementation (p = 0.059) but there was no difference between control and
inulin supplementation (p = 0.75). However, there were no differences in the baseline measurements
or the AUC0-420 for peripheral PYY or GLP-1 concentrations or CAS between treatments (Table 2;
Figure S2).
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Table 1. Baseline characteristics of subjects and changes in anthropometric measurements and blood lipid profiles between study visits.
Control-FP 4 Inulin-FP 5 IPE-FP 6 P 7
Male n (%) 9/21 (43%)
Age (year) 60 [53, 64]
Weight (kg) 80.2 [76.1, 88.4] 80.5 [75.9, 88.5] 81.7 [76.2, 89.5] # $ 0.023
FFM (kg) 51.5 [46.2, 66.0] 50.9 [46.5, 67.2] 51.6 [47.3, 67.5] ## 0.024
FM (kg) 29.1 [23.3, 33.7] 28.8 [23.3, 32.8] 29.2 [24.2, 32.8] 0.48
% FFM 65 [59.9, 74.0] 65.5 [60.3, 74.9] 64.8 [60.1, 74.3] 0.16
% FM 35 [26.0, 40.2] 34.5 [25.2, 40.0] 35.2 [25.8, 40.0] 0.15
TBW 37.7 [33.9. 48.3] 37.2 [34.1, 49.2] 37.8 [34.6, 49.4] ## $ 0.026
Fasting cholesterol (mmol/L)
Total 5.1 [4.8, 6.4] 5.0 [4.6, 6.1] 5.3 [4.7, 5.9] 0.86
HDL 1.5 [1.3, 1.9] 1.4 [1.2, 1.7] 1.5 [1.3, 1.8] 0.92
LDL 3.1 [2.5, 4.1] 3.0 [2.3, 4.0] 3.1 [2.5, 3.8] 0.95
Total Chol:HDL 3.6 [2.8, 4.6] 3.7 [2.9, 4.6] 3.8 [2.9, 4.4] 0.97
LDL:HDL 2.1 [1.6, 3.1] 2.3 [1.6, 2.9] 2.4 [1.6, 2.7] 0.87
Fasting TG (mmol/L) 1.2 [1.0, 1.6] 1.2 [1.0, 1.7] 1.3 [0.9, 1.7] 0.10
Power of food scale 35 [26, 42] 33 [25, 44] 33 [24, 46] 0.68
IPAQ 1,2 4230 [2025, 6115] 3570 [2280, 6678] 3750 [1504, 5190] 0.85
24 h food intake (kcal) 3 2250 [1681, 2737] 1948.5 [1800, 2358] 2222 [1775, 2547] 0.95
Data are presented as median [IQR]. Data represent n = 21, except for 1 where n = 14. 2 IPAQ captured data relating to daily activity from the previous week. 3 Subjects completed
diet diaries on the day before each study visit, which were assessed using Dietplan 6 software. 4 Control data were collected on the control study visit where participants consumed
unsupplemented food products. 5 Inulin-FP and 6 IPE-FP data were collected on the post-supplementation visits. 7 Data compared using a Friedman test with significant differences
highlighted in bold. # and ## indicate a significance between Control-FP and IPE-FP of p < 0.05 and p < 0.01, respectively, in post-hoc tests. $ indicates a significance between Inulin-FP and
IPE-FP of p < 0.05 in post-hoc tests. Abbreviations: BMI, body mass index; FFM, fat-free mass; high-density lipoproteins, HDL; IPAQ; International Physical Activity Questionnaire; IPE,
inulin-propionate ester; FP, food products; LDL, low-density lipoprotein; NEFA, non-esterified fatty acids; TBW, total body water; TG, triglycerides.
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Table 2. Ad libitum energy intake, gut hormone and composite appetite score measures following a seven-day supplementation with inulin-FP or IPE-FP compared
to control-FP.
Unit Value Control-FP 2 Inulin-FP 3 IPE-FP 4 P 5
Energy intake kcal 830.8 [643.7, 1158.3] 878.5 [415.4, 1112] 699.2 [398.6, 1053.3] 0.012
PYY pmol/L 0 min 47.30 [29.35, 57.69] 44.29 [28.29, 54.91] 46.16 [29.85, 61.50] 0.41
AUC0-420 53.41 [43.6, 70.31] 58.51 [42.88, 70.80] 54.86 [44.91, 68.16] 0.95
GLP-1 pmol/L 0 min 20.98 [14.72, 28.04] 18.63 [16.33, 22.50] 20.08 [13.34, 24.78] 0.26
AUC0-420 22.73 [18.55, 26.34] 22.88 [17.60, 24.94] 21.77 [17.67, 26.18] 0.10
CAS 1 mm 0 min 50.0 [40.0, 70.5] 58.0 [41.5, 79.0] 50.0 [37.0, 76.5] 0.86
AUC0-420 25.7 [11.8, 43.5] 23.3 [10.2, 45.0] 34.9 [15.8, 41.3] 0.28
Data are presented as median [IQR]. Data represent n = 21, except for 1 where n = 19. 2 Control data were collected on the control study visit where participants consumed unsupplemented
food products. 3 Inulin-FP and 4 IPE-FP data were collected on the post-supplementation visits. 5 Data compared using a Friedman test with significant differences highlighted in bold.
Abbreviations: AUC, area under the curve; CAS, composite appetite score; IPE, inulin-propionate ester; FP, food products.
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3.3. Food Product Taste and Appearance Ratings and Side Effects
There were no differences in bread roll or fruit smoothie taste and appearance ratings between
treatments (p = 0.25–0.89) (Table 3). There was a significant difference in stomach discomfort, nausea,
flatulence, heartburn and toilet frequency between treatments (Figure 1). Post hoc tests revealed that,
compared to control, stomach discomfort, nausea, flatulence, heartburn and toilet frequency were all
significantly increased following inulin (p = 0.001–0.021) and IPE (p = 0.004–0.043) supplementation.
However, there was no significant difference in these side effects between supplements (p = 0.245–0.86).
There was also a trend for a difference in stomach discomfort between treatments but this did not reach
statistical significance (p = 0.053). There was no difference in bloating and belching between treatments.
Table 3. Food product satisfaction ratings for inulin-FP and IPE-FP compared to control-FP 1.
Food Product Control-FP 2 Inulin-FP 3 IPE-FP 4 P 5
Bread
Overall 6 [4, 8] 6 [4, 8] 6 [4, 8] 0.70
Appearance 5 [5, 7] 6 [5, 7] 6 [5, 7] 0.46
Aroma 6 [5, 7] 6 [5, 7] 6 [5, 7] 0.85
Flavour 7 [5, 8] 6 [5, 8] 6 [4, 8] 0.29
Texture 5 [4, 7] 5 [4, 7] 5 [4, 7] 0.79
Smoothie
Overall 7 [7, 8] 7 [6, 8] 7 [5, 8] 0.53
Appearance 6 [5, 8] 7 [5, 8] 7 [5, 8] 0.89
Aroma 6 [5, 8] 7 [5, 8] 6 [5, 7] 0.50
Flavour 7 [7, 8] 7 [6, 9] 6 [4, 8] 0.25
Texture 7 [6, 8] 7 [4, 7] 7 [6, 8] 0.52
Data are presented as median [IQR] (n = 21). 1 Participants rated the product overall, and based on its appearance,
aroma, flavour and texture. Participants ticked a box between 1 and 9, where 1 was labelled with “dislike extremely”,
5 was labelled with “neither like nor dislike” and 9 was labelled with “like extremely”. 2 Control data were collected
on the control study visit where participants consumed unsupplemented food products. 3 Inulin-FP and 4 IPE-FP
data were collected on the post-supplementation visits. 5 Data were compared using a Friedman test. Abbreviations:
FP, food products; IPE, inulin-propionate ester.
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Figure 1. Gastrointestinal side effects following a seven-day supplementation with inulin-FP or IPE-FP
compared to control-FP. Data repr sents median [IQR] gastrointestina side-effects ratings (A) Stomach
Discomfort, (B) Nausea, (C) Bloating, (D) Flatulence, (E) Heartburn, (F) Belch g, (G) Toil t More Often
and (H) Toilet Less Of en, which were made using 100 mm VAS (n = 21). Subjects were asked to rate
the occurrence of each side eff ct with extreme stat ments anchored at each end of the rating scale
(0 mm Never, 100 mm All the time). * and ** indicate a significance b tween treatments of p < 0.05 and
p < 0.01, resp ctively, in post-hoc tests. Abbreviations: VAS, visual an lo ue scale.
3.4. Resting Energy Expenditure and Substrate Oxidation
Th re was a trend for a difference in fasting REE between treatments (Table 4). There was a
significant difference in the AUC0-240 for postprandial REE between treatments. This was due to greater
REE following IPE-FP when compared to inulin (p = 0.021) and control (p = 0.011). However, due to
significant differences in body composition noted between treatments, REE corrected for FFM was
calculated. After correcting for changes in FFM, there was no significant difference in REE between
treatments (p = 0.22–0.37). There were no significant differences in RER or carbohydrate, lipid and
protein oxidation between treatments (p = 0.33–0.95) .
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Table 4. Fasting values and AUC for energy expenditure and substrate oxidation, and after correcting for fat-free mass, following a seven-day supplementation with
inulin-FP or IPE-FP compared to control-FP.
Unit Value 1 Control-FP 2 Inulin-FP 3 IPE-FP 4 P 5
RER VCO2/VO2 0 min 0.762 [0.725, 0.787] 0.764 [0.712, 0.824] 0.766 [0.683, 0.813] 0.71
AUC0-240 0.823 [0.756, 0.841] 0.825 [0.773, 0.875] 0.842 [0.745, 0.859] 0.95
Raw
REE kcal/min 0 min 1.031 [0.936, 1.179] 1.103 [0.909, 1.197] 1.121 [0.974, 1.276] 0.051
AUC0-240 1.144 [1.073, 1.271] 1.152 [1.056, 1.275] 1.255 [1.091, 1.321] # $ 0.018
CHO Ox. g/min 0 min 0.037 [-0.024, 0.051] 0.041 [−0.015, 0.083] 0.042 [−0.058, 0.091] 0.87
AUC0-240 0.094 [0.024, 0.136] 0.097 [0.056, 0.162] 0.102 [0.013, 0.163] 0.78
Lipid Ox. g/min 0 min 0.071 [0.055, 0.089] 0.076 [0.038, 0.085] 0.078 [0.046, 0.115] 0.86
AUC0-240 0.054 [0.033, 0.072] 0.050 [0.032, 0.082] 0.052 [0.032, 0.099] 0.33
Protein Ox. g/min total 0.057 [0.049, 0.065] 0.058 [0.042, 0.062] 0.057 [0.042, 0.065] 0.95
FFM corr. 6
REE kcal/min/kg FFM 0 min 0.020 [0.016, 0.022] 0.020 [0.016, 0.022] 0.021 [0.017, 0.022] 0.37
AUC0-240 0.021 [0.017, 0.025] 0.021 [0.018, 0.024] 0.022 [0.018, 0.024] 0.22
CHO Ox. mg/min/kg FFM 0 min 0.718 [−0.346, 0.940] 0.734 [-0.245, 1.751] 0.663 [−1.028, 1.364] 0.95
AUC0-240 1.849 [0.388, 2.817] 1.881 [1.087, 3.073] 1.900 [0.159, 3.011] 0.83
Lipid Ox. mg/min/kg FFM 0 min 1.470 [0.934, 1.652] 1.238 [0.789, 1.634] 1.345 [0.950, 1.770] 0.87
AUC0-240 1.024 [0.638, 1.272] 1.006 [0.614, 1.365] 0.921 [0.640, 1.610] 0.72
Protein Ox. mg/min/kg FFM total 1.080 [0.869, 1.261] 0.965 [0.817, 1.216] 0.978 [0.810, 1.199] 0.67
Data are presented as median [IQR)] (n = 21). 1 AUC were calculated using the trapezoidal rule and then divided by the relevant time period (240 min). 2 Control data were collected on the
control study visit where participants consumed unsupplemented food products. 3 Inulin-FP and 4 IPE-FP data were collected on the post-supplementation visits. 5 Data represents the
difference between post-supplementation and control measurements. 5 Data compared using a Friedman test with significant differences and trends highlighted in bold. 6 REE and
substrate oxidation measurements after correcting for FFM. # indicates a significance between Control-FP and IPE-FP and $ indicates a significance between Inulin-FP and IPE-FP of
p < 0.05 in post-hoc tests. Abbreviations: AUC, area under the curve; CHO, carbohydrate; corr., corrected; FFM, fat free mass; FP, food products; IPE, inulin-propionate ester; Ox, oxidation;
REE, resting energy expenditure; RER, respiratory exchange ratio.
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3.5. Breath H2
There was no difference in fasting breath H2 concentrations between treatments (p = 0.44; Table 5).
There was a significant difference in the AUC0-420 and the AUC24o-420 for breath H2 between treatments.
This was due to greater breath H2 following inulin supplementation versus control (AUC0-420 p = 0.002,
AUC24o-420 p = 0.002) and IPE (AUC0-420 p = 0.027, AUC24o-420 p = 0.014) owing to the greater amount
of fermentable carbohydrate in inulin-FP than in IPE-FP (10 g compared with 7.3 g) and control-FP.
However, breath H2 concentrations were significantly elevated above baseline concentrations between
240 and 420 min following consumption of IPE-FP (p < 0.01; Figure S2B). This suggests fermentation
of IPE and release of propionate in the colon occurred in a time course similar to that previously
reported [10,21]. Breath H2 concentrations were also consistently elevated above baseline concentrations
between 240 and 420 min after receiving inulin-FP (p < 0.01).
3.6. Blood Hormones and Metabolites
There were no differences in the baseline measurements or the AUC0-420 for peripheral glucose,
insulin, NEFA or SCFA concentrations between treatments (Table 5; Figure S2E–J).
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Table 5. Fasting values and AUC for breath H2, blood hormones and metabolites following a seven-day supplementation with inulin-FP or IPE-FP compared
to control-FP.
Unit Value 1 Control-FP 2 Inulin-FP 3 IPE-FP 4 P 5
Breath H2 ppm 0 min 4.0 [1.5, 11.0] 5.0 [2.0, 11.0] 3.0 [1.5, 11.0] 0.44
AUC0-420 11.0 [6.0, 20.5] 18.4 [7.5, 31.6] ** 11.7 [6.2, 20.0] $ 0.010
AUC0-240 6.1 [3.2, 9.3] 7.4 [5.2, 14.8] 7.4 [4.6, 13.1] 0.54
AUC240–420 17.8 [7.9, 27.8] 32.3 [12.0, 50.6] ** 16.7 [7.7, 31.6] $ 0.004
Glucose mmol/L 0 min 5.43 [5.06, 5.74] 5.44 [5.25, 5.76] 5.33 [5.01, 5.70] 0.87
AUC0-420 6.00 [5.61, 6.91] 6.13 [5.63, 6.60] 6.10 [5.88, 6.81] 0.17
Insulin µU/ml 0 min 2.28 [2.04, 2.70] 2.34 [2.26, 2.71] 2.37 [2.16, 2.61] 0.10
AUC0-420 48.20 [37.44, 57.51] 51.8 [40.15, 61.10] 54.49 [39.10, 59.75] 0.41
NEFA mmol/L 0 min 0.71 [0.59, 0.83] 0.66 [0.48, 0.77] 0.64 [0.40, 0.74] 0.11
AUC0-420 0.14 [0.10, 0.18] 0.11 [0.08, 0.16] 0.11 [0.08, 0.15] 0.16
Acetate µmol/L 0 min 51.75 [41.27, 61.05] 54.46 [42.50, 74.29] 54.90 [34.90, 73.19] 0.95
AUC0-420 58.72 [36.64, 73.71] 56.35 [45.23, 72.60] 57.64 [44.18, 76.70] 0.18
Propionate µmol/L 0 min 2.20 [1.53, 2.54] 2.37 [1.88, 2.88] 2.30 [1.70, 3.06] 0.26
AUC0-420 1.92 [1.68, 2.78] 2.27 [1.63, 2.53] 2.38 [2.04, 2.83] 0.10
Butyrate µmol/L 0 min 1.17 [0.46, 1.45] 1.29 [0.94, 1.72] 1.04 [0.67, 1.64] 0.41
AUC0-420 1.21 [0.83, 1.56] 1.11 [0.96, 1.36] 1.28 [1.00, 1.62] 0.47
Data are presented as median [IQR] (n = 21). 1 AUC were calculated using the trapezoidal rule and then divided by the relevant time period (180 or 240 min) with AUC0-420 representing
the total AUC and the AUC0-240 and AUC240–420 representing before and after >80% IPE has been shown to enter the colon, respectively [10]. 2 Control data were collected on the control
study visit where participants consumed unsupplemented food products. 3 Inulin-FP and 4 IPE-FP data were collected on the post-supplementation visits. 5 Data compared using a
Friedman test with significant differences highlighted in bold. ** indicates a significance between Control-FP and Inulin-FP of p < 0.01 in post-hoc tests. $ indicates a significance between
Inulin-FP and IPE-FP of emphp < 0.05 in post-hoc tests. Acetate, propionate and butyrate were measured according to a previously published method [20]. Abbreviations: AUC, area
under the curve; CAS, composite appetite score; FP, food products; GLP-1, glucagon like peptide-1; IPE, inulin-propionate ester; NEFA, non-esterified fatty acids; PYY, peptide YY.
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4. Discussion
Investigating the physiological impact of SCFA in humans has long been hampered by our inability
to undertake meaningful intervention studies where we are able to control the site, rate and extent
of SCFA production in the GI tract. Oral SCFA are unpalatable and are not sustainable as a dietary
intervention strategy. Encapsulation or other routes of duodenal delivery are possible but whether
small intestinal and large intestinal SCFA behave in a physiologically identical manner remains to be
elucidated. However, as L cells that co-express GLP-1 and PYY increase in density along the GI tract it
has been suggested that increasing colonic propionate delivery or production is more likely to lead to a
suppression in appetite than increasing small intestinal propionate content [22]. Direct and controlled
delivery of individual SCFA to the proximal colon, the site of maximal production in the GI tract, has
been achieved with IPE and represents a step-change in our ability to investigate the role of SCFA in
human health. In the present study, we incorporated a 10 g/d dose of IPE into FP in order to assess
their effect on appetite and energy expenditure. IPE-supplemented-FP (bread roll + fruit smoothie)
provided a 10 g/d dose of IPE when consumed together, which is the dose that has previously been
shown to modulate appetite responses [10,14,21], and increase daily propionate production by 2.5-fold
based on the average UK non-starch polysaccharide intake [10].
Previous studies have shown a reduction in ad libitum energy intake following the consumption of
IPE [10,14,21]. As hypothesised, there was a significant difference in energy intake between treatments,
which was driven by a greater suppression in appetite following IPE-FP versus both inulin-FP and
control-FP (p = 0.056–0.059). Despite the difference in ad libitum energy intake, there was no difference
in the CAS. However, this is in line with previous studies [10,21], suggesting that IPE does not suppress
subjective appetite responses, but reduces energy intake, consistent with the action of a physiological
satiation signal. It was originally hypothesised that any reduction in energy intake following IPE-FP
would be mediated by an increase in PYY and GLP-1 concentrations, as elevated colonic propionate
has previously been shown to stimulate gut hormone secretion acutely in humans [10]. However, we
found no difference in GLP-1 or PYY concentrations following a seven-day IPE supplementation, which
is in line with previous findings following long-term supplementation with IPE [10]. Other studies
have also reported that non-digestible carbohydrates (NDC) consumption and increased colonic SCFA
production improve body composition and reduce energy intake independent of changes in systemic
gut hormone concentrations in rodents [23–25]. It is possible that we were not able to detect differences
in gut hormone release as it has previously been highlighted that venous sampling measurements are
not always reflective of gut hormone release into the portal vein [26]. However, alternative mechanisms
may also be responsible. It is possible that these appetite suppressing effects may be a result of elevated
portal propionate concentrations; portal propionate has been shown to induce vagal signalling via
FFAR3 [12,27,28] and ruminant studies have shown an association between elevated portal propionate
concentrations and a reduction in energy intake [29,30].
The results of the food product ratings demonstrate that IPE-FP were palatable to the participants.
Furthermore, the gastrointestinal side effects noted following IPE-FP are comparable to those
reported following supplementation with inulin-FP, and are common side effects associated with fibre
consumption. Thus, the incorporation of IPE into FP allows for the delivery of IPE in conditions that
more accurately reflect the way humans eat but also provides an attractive way to deliver IPE on a
population scale.
Oral SCFA have previously been shown to protect against weight gain in HFD-fed mice without
changing food intake or physical activity levels, which suggests that SCFA may affect EE and/or
substrate oxidation [11,31,32]. Rectal propionate infusions and oral propionate supplementation have
previously been reported to increase REE in humans [13,33]. In the present study there was a trend for
a difference in fasted REE between treatments and a significant increase in postprandial REE following
IPE-FP compared to inulin (0.103 kcal/min) and control (0.111 kcal/min). Theoretically, if this effect was
sustained over a period of 24 h, this would result in an increase in EE of ~148–160 kcal/d. If consumed
daily, this small increase in EE may be beneficial in helping prevent “weight creep”, which causes the
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average adult to gain 0.4–0.9 kg/year [34,35]. However, due to the differences in body composition
between treatments, the REE was corrected for FFM, the primary determinant of REE [36]. After
correcting for FFM, the effect was no longer significant. Colonic and rectal infusions of SCFA have been
reported to increase lipid oxidation in humans [33,37]. In addition, oral supplementation with sodium
propionate has been shown to increase lipid oxidation in humans [13]. It was, therefore, originally
hypothesised that an increase in REE would be driven by a shift in substrate utilization towards
fat oxidation. However, no significant difference in substrate oxidation was noted in the present
study between treatments based on the indirect calorimetry data. As REE measurements were not
collected for the whole 420 min postprandial sampling period, it is possible that significant differences
in REE or substrate oxidation between supplementation treatments were missed. In addition, it is
currently unknown whether increased SCFA delivery to the small versus large intestine have different
physiological effects and warrants further investigation.
There was a significant difference in the AUC0-420 and the AUC240–420 for breath H2 between
treatments, which was driven by higher breath H2 concentrations following the consumption of
inulin-FP versus IPE-FP and control-FP [10]. However, this is a consistent observation for inulin
compared with other fermentable carbohydrates and may also reflect that the 10g/day intended inulin
dose delivered in inulin-FP contained more inulin than IPE-FP (~7g/day allowing for propionate content
in 10 g IPE) and control-FP. Despite the differences between treatments, breath H2 concentrations were
significantly elevated above baseline concentrations from 240–420 min to the end of the study visit
following the consumption of IPE-FP and inulin-FP, suggesting fermentation of inulin and IPE share a
similar time course and similar to that previously reported and at the time of the ad libitum meal [10].
There were no significant differences in serum SCFA concentrations between treatments, thus
despite the delivery of a large amount of propionate to the colon this is not translated into significantly
higher circulating propionate concentrations. However, this is unsurprising as propionate has
been shown to be effectively sequestrated by the liver [38] and a recent report has highlighted that
propionate levels in peripheral blood are an inaccurate reflection of the amounts being produced
and absorbed from the gut [39]. Nevertheless, previously we have reported a significant increase in
propionate 13C enrichment in the peripheral circulation following the consumption of a 13C labelled
IPE variant, confirming that the bound propionate from IPE is absorbed from the gut and is available
systemically [10].
As propionate is a potential gluconeogenic precursor [40], fasting and postprandial blood glucose
and insulin concentrations were measured. There was no differences in the baseline values or the AUC
for glucose, insulin or NEFA between treatments. However, these results are in line with previous
studies [10,21].
Interestingly, body weight was significantly higher following IPE-FP versus control and inulin-FP.
There were no differences between treatments in FM, however, FFM was significantly higher following
IPE-FP versus control. There is some evidence that NDC supplementation can increase FFM [41]
or preserve FFM during weight loss [42,43] in humans. However, due to the short seven day
supplementation period it is unlikely that the differences observed is due to the IPE-FP. Furthermore,
TBW was significantly higher following supplementation with IPE versus control and inulin-FP, which
suggests that greater water retention following IPE may be driving the differences in body weight
and composition noted. As there was a >14-day washout period between supplementation periods
and body composition was not recorded prior to IPE supplementation, we cannot be certain that the
observed effects on body weight or body composition were due to the relatively short supplementation
period and thus these data must be treated with caution.
The addition of IPE to whole foods was a major strength to this study, providing opportunities for
long-term intervention studies with IPE, which can be consumed as part of a normal habitual diet that
is both palatable and versatile. However, further work is needed to understand whether IPE has the
potential to increase REE. As propionate has previously been shown to stimulate sympathetic nervous
system (SNS) activity resulting in an increase in EE via FFAR3 [44] it would be of interest to measure
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markers of SNS activity, such as heart rate, in order to investigate this as a possible mechanism for
increased EE in future studies. A possible limitation in the current study is that participants were not
counselled or advised on how to replace habitual dietary intake with the study foods. However, if
the addition of FP resulted in the consumption of a surplus of calories during the supplementation
periods, any effect of this is likely to be controlled for due to the crossover design.
5. Conclusions
IPE added to common food products does not influence palatability. The increased colonic
propionate delivery reduced ad libitum energy intake independent of changes in peripheral plasma PYY
and GLP-1. Thus, the underlying mechanism for IPE’s appetite-suppressing effect remains unknown.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/4/861/s1,
Figure S1. Study overview, Figure S2. Timecourse data for breath H2, blood hormones and metabolites following
a seven-day supplementation with inulin-FP or IPE-FP compared to control-FP, Table S1. Study food product
nutritional information.
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